| abstract |
The present application relates to compositions and methods for analysing and characterizing patients affected by colorectal cancer, and, in particular those affected by locally advanced stage II and stage III cancer of the rectum. The application concerns in particular, the methods and reagents (primers, chips, DNA chips, probes, NGS, real-time PCR, etc.) to determine or evaluate the clinical development of such cancers, and more particularly to assess the manner in which they respond to RCT treatment and/or to determine the risk of metastatic recurrence in said patients. The invention is based in particular on the detection of circulating miRNAs. It can be used on any patient, and in particular on patients having a stage II or stage III cancer. |